PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 07:00 ET
|
PDS Biotechnology Corporation
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology...
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
August 04, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech to Participate at BTIG Biotechnology Conference 2022
August 02, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results
July 26, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting
July 14, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel
June 03, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101
June 02, 2022 08:00 ET
|
PDS Biotechnology Corporation
PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM...
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
May 31, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
May 26, 2022 17:02 ET
|
PDS Biotechnology Corporation
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck...
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022
May 26, 2022 17:01 ET
|
PDS Biotechnology Corporation
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months 75% of CPI naïve patients alive at median follow up of 17 months Anti-tumor objective responses seen in...